Clinical Characteristics of Progressive Pulmonary Fibrosis of Idiopathic Pulmonary Fibrosis Patients Who Receive Anti-fibrotic Agent

被引:0
|
作者
Kishaba, T. [1 ]
Nagano, H. [2 ]
机构
[1] Okinawa Chubu Hosp, Resp Med, Uruma, Japan
[2] Okinawa Chubu Hosp, Resp Med, Uruma, Japan
关键词
D O I
暂无
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
A1519
引用
收藏
页数:2
相关论文
共 50 条
  • [31] A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
    Katy M. Roach
    Amanda Sutcliffe
    Laura Matthews
    Gill Elliott
    Chris Newby
    Yassine Amrani
    Peter Bradding
    [J]. Scientific Reports, 8
  • [32] Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
    Moor, Catharina
    Kimman, Merel L.
    van Manen, Mirjam J. G.
    Dirksen, Carmen D.
    Wijsenbeek, Marlies S.
    Van Jaarsveld, F. Xana
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [33] WEIGHT LOSS HAS A SIGNIFICANT IMPACT ON ANTI-FIBROTIC DRUG TOLERANCE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Moon, R. D. C.
    Barker, E.
    Agnew, S.
    Sutcliffe, J.
    Kwok, A.
    Spencer, L. G.
    [J]. THORAX, 2017, 72 : A250 - A250
  • [34] Anti-Fibrotic Role Of Inhaled Interferon-γ Detected By Proteomic Studies In Patients With Idiopathic Pulmonary Fibrosis
    Hasaneen, N. A.
    Haley, J.
    Foda, H. D.
    Condos, R.
    Smaldone, G. C.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [35] Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
    Takumi Yoshikawa
    Mitsuo Otsuka
    Hirofumi Chiba
    Kimiyuki Ikeda
    Yuki Mori
    Yasuaki Umeda
    Hirotaka Nishikiori
    Koji Kuronuma
    Hiroki Takahashi
    [J]. BMC Pulmonary Medicine, 20
  • [36] Efficacy of Anti-Fibrotic Treatments and Prognosis in Progressive Fibrosing Interstitial Lung Diseases Other Than Idiopathic Pulmonary Fibrosis
    Sugino, K.
    Ono, H.
    Shimizu, S.
    Kurosawa, T.
    Ando, M.
    Mori, K.
    Kishi, K.
    Homma, S. A.
    Tsuboi, E.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [37] Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing
    Burgess, Andrew
    Goon, Ken
    Brannan, John D.
    Attia, John
    Palazzi, Kerrin
    Oldmeadow, Christopher
    Corte, Tamera J.
    Glaspole, Ian
    Goh, Nicole
    Keir, Gregory
    Allan, Heather
    Chapman, Sally
    Cooper, Wendy
    Ellis, Samantha
    Hopkins, Peter
    Moodley, Yuben
    Reynolds, Paul
    Zappala, Chris
    Macansh, Sacha
    Grainge, Christopher
    [J]. RESPIROLOGY, 2019, 24 (10) : 988 - 995
  • [38] Anti-fibrotic effect of FGF21 in pulmonary fibrosis
    Ghanem, Mada
    Archer, Gabrielle
    Justet, Aurelien
    Hachem, Mouna
    Boghanim, Tiara
    Vadel, Aurelie
    Pote, Nicolas
    Cazes, Aurelie
    Mordant, Pierre
    Castier, Yves
    Mal, Herve
    Jaillet, Madeleine
    Mailleux, Arnaud
    Crestani, Bruno
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [39] The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study
    Aoki, Ayako
    Hara, Yu
    Fujii, Hiroaki
    Murohashi, Kota
    Nagasawa, Ryo
    Tagami, Yoichi
    Enomoto, Tatsuji
    Matsumoto, Yutaka
    Masuda, Makoto
    Watanabe, Keisuke
    Horita, Nobuyuki
    Kobayashi, Nobuaki
    Kudo, Makoto
    Ogura, Takashi
    Kaneko, Takeshi
    [J]. PLOS ONE, 2023, 18 (09):
  • [40] Comparison of clinical characteristics and prognosis in patients with idiopathic pulmonary upper lobe predominant pulmonary fibrosis and idiopathic pulmonary fibrosis
    Ohkubo, Hirotsugu
    Fukumitsu, Kensuke
    Fukuda, Satoshi
    Kanemitsu, Yoshihiro
    Takemura, Masaya
    Maeno, Ken
    Ito, Yutaka
    Niimi, Akio
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52